drugset / Trial / NCT03239756
Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a single-center, open-label, dose-escalating study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of single and multiple subcutaneous injection TK006 in patients with breast cancer-related bone metastases.
Timeline
- Start
- 2017-07-20
- Primary completion
- 2018-08
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Denosumab | Monoclonal antibody | 60 mg | Subcutaneous |
| Subject | Denosumab | Monoclonal antibody | 120 mg | Subcutaneous |
| Subject | Denosumab | Monoclonal antibody | 180 mg | Subcutaneous |